Will ATAI's CEO or CFO disclose open-market net selling of more than $500K via Form 4 in 2026?

Base rate for CEO/CFO open-market net selling exceeding $500K in a calendar year for 5-year-post-IPO biotechs with 300%+ YTD rallies: approximately 45-55%. Adjust down for Breakthrough Therapy narrative-preservation incentive (-8%). Adjust up for year-5 vesting timing and Delaware redomiciliation simplifying 10b5-1 admin (+3%). Net 0.38. The CMO precedent argues for executive comfort with open-market liquidation.

Biotech CEOs and CFOs with Breakthrough-designated lead assets tend to suppress open-market selling to preserve the narrative signal. Post-merger executive teams may have significant Beckley-legacy equity already monetized via merger close-out, reducing pressure to access Form 4 open-market sales. MNPI restrictions during Phase 3 enrollment windows further limit trading opportunities. 0.35 — moderately below base rate.

Slightly higher. The CMO precedent suggests management team has already demonstrated willingness to liquidate open-market — if one executive has done so, others may follow after lock-up expirations or through 10b5-1 plans adopted in 2025 (now trading in 2026). The 341% YTD rally creates strong personal financial incentive. $500K threshold is modest for senior biotech executives with significant equity grants — a single pre-scheduled sale of ~50K shares at current prices exceeds the threshold. Net 0.42.

Balanced. Modal outcome: one or more executives adopts 10b5-1 plan in 2025-2026 and plan triggers trades in 2026 totaling more than $500K. Counter-modal: MNPI restrictions during Phase 3 enrollment windows limit trading days; executives may prefer to hold through Phase 3 primary-endpoint data. Net 0.38 reflects roughly coin-flip with slight downward tilt for narrative preservation.

Conservative. Committee flagged the CMO's liquidation as suboptimal timing — management team has received this feedback and may be more cautious with CEO/CFO timing. Fiduciary-optics concern during Phase 3 catalyst window is meaningful. 0.33.

The $500K threshold is low enough that pre-scheduled 10b5-1 plans easily trigger it even at modest share counts. Most Breakthrough-stage biotechs with executives over 50+ years old have estate/diversification motivations that produce some open-market selling. Net 0.40 reflects the mechanical likelihood of threshold-triggering under normal portfolio management, counterbalanced by narrative suppression.

Biotech CEO/CFO open-market selling with 300%+ YTD rally: approximately 45% base rate. Breakthrough suppression -8%. Net 0.38.

CMO precedent + year-5 vesting + rally + low $500K threshold all argue for YES. Narrative preservation and MNPI restrictions argue NO. Split 0.36.

Mid-range. Breakthrough-stage executives with rallied stock typically sell some portion through 10b5-1 plans. $500K is not a high bar. 0.40.